Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

b cell malignancies, b-cell leukemia, b cell lymphoma, bispecific chimeric antigen receptor (car) t cells, relapsed or refractory (r/r) b-cell malignancies, bispecific anti-cd19, anti-cd20 car t cell therapy, lymphapheresis, lymphodepleting (non- myeloablative) chemotherapy, immune effector cell-associated neurotoxicity syndrome (icans), cytokine release syndrome (crs), immune effector cell-associated haematotoxicity (icaht), european group for blood and marrow transplantation (ebmt)